Implementation of a Rapid Genotypic Assay to Promote Targeted Ciprofloxacin Therapy of Neisseria gonorrhoeae in a Large Health System | Zendy

LaoTzu AllanBlitz | Zendy; Romney M. Humphries | Zendy; Peera Hemarajata | Zendy; Ashima Bhatti | Zendy; Mark Pandori | Zendy; Mark J. Siedner | Zendy; Jeffrey D. Klausner | Zendy

Open Access

Implementation of a Rapid Genotypic Assay to Promote Targeted Ciprofloxacin Therapy of Neisseria gonorrhoeae in a Large Health System

Author(s) -

LaoTzu AllanBlitz,

Romney M. Humphries,

Peera Hemarajata,

Ashima Bhatti,

Mark Pandori,

Mark J. Siedner,

Jeffrey D. Klausner

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw864

Subject(s) - neisseria gonorrhoeae , ciprofloxacin , medicine , ceftriaxone , dna gyrase , microbiology and biotechnology , gonorrhea , genotype , ofloxacin , neisseria , antibiotics , virology , biology , bacteria , genetics , escherichia coli , human immunodeficiency virus (hiv) , gene

Multidrug-resistant Neisseria gonorrhoeae is a top threat to public health. In November 2015, UCLA Health introduced a rapid gyrase A (gyrA) genotypic assay for prediction of Neisseria gonorrhoeae susceptibility to ciprofloxacin. We found a significant reduction in ceftriaxone use with a concomitant increase in targeted therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research